The chief executive of a leading Alzheimer’s charity has hailed a “historic moment” after US regulators approved the first new drug to treat the disease in almost 20 years, offering fresh hope for millions of patients worldwide. 

Hilary Evans, chief executive at Alzheimer’s Research UK, told Reaction that the FDA’s approval was the source of “cautious optimism” and that while more data was needed, “overall this gives great comfort to people who have been diagnosed with a disease where there are no treatments”.